NVDA+2.54%AAPL+1.32%GOOGL−1.62%MSFT+0.20%AMZN−0.10%TSM+1.60%SPCX+7.79%META+0.47%
StockVS

NASDAQ · Biotechnology · USD

PMV Pharmaceuticals, Inc. (PMVP) Stock Analysis

PMV Pharmaceuticals, Inc. (PMVP) is a Biotechnology stock listed on NASDAQ and quoted in US Dollar.

Last Updated: October 21, 2026

PMVP

$1.36

−$0.03 (−2.16%)

Oct 21, 2026 · Market close

Compare

Price History

Hover for the daily close. The dotted line marks the period open.

Compare PMVP with… →

PMVP Key Statistics

As of Oct 21, 2026
Trading
Open
$1.37
Previous Close
$1.39
Day's Range
1.35–1.41
52-Week Range
1.02–1.91
Volume
236.57K
BetaHow much the share price moves relative to the wider market. 1.0 moves in line with it; above 1.0 swings more, below 1.0 less.
1.35
Valuation
Market Cap
$102.70M
P/E Ratio
unprofitable
EPS (ttm)Profit attributable to each share over the last twelve months.
−1.42
Financials (FY)
Revenue (FY)
$0.00
Net Income (FY)
−$77.74M
Shares OutstandingThe total number of shares held by all investors. Market value is this figure multiplied by the share price.
75.51M
1-Year Return
−11.11%
Dividend and dates
Earnings Date
November 16, 2026estimated
Avg Volume
667.61K

Only metrics the company reports are shown. Data provided by Yahoo Finance via yfinance. Updated daily.

Key facts

As of October 21, 2026, PMVP closed at $1.36, −11.11% over 1 year.

PMV Pharmaceuticals, Inc. (PMVP) has a market capitalization of $102.70M.

In fiscal 2025, PMVP reported revenue of $0.00.

PMVP Stock Return by Calendar Year

PMV Pharmaceuticals, Inc. (PMVP) return since Sep 2020: what $10,000 became

1 year
$10,000 $8,889
−11.11%
5 years
$10,000 $587
−94.13%
Since Sep 2020
$10,000 $363
−96.37%

If you had invested $10,000 in PMV Pharmaceuticals, Inc. (PMVP) at the close on September 25, 2020, the earliest close on record here, it would have been worth $363 at the close on October 21, 2026: −96.37% in total, −42.10% a year, over a partial period shorter than 10 years. A historical calculation from closing prices adjusted for splits and dividends, before fees and taxes.

Calendar-year returns computed from daily closing prices. Partial years are shown muted and marked with an asterisk.

YearReturn
2026 (partial year)+8.80%
2025−17.22%
2024−51.29%
2023−64.37%
2022−62.34%
2021−62.45%
2020 (partial year)+63.98%

As of October 21, 2026.

PMVP Revenue and Earnings by Fiscal Year

FY ends December
Fiscal yearRevenueNet incomeNet margin
2025$0.00−$77.74M—
2024$0.00−$58.71M—
2023$0.00−$68.96M—
2022$0.00−$73.32M—
Fiscal yearRevenueGross profitOperating incomeNet incomeNet margin
2025$0.00—−$86.21M−$77.74M—
2024$0.00—−$85.45M−$58.71M—
2023$0.00—−$80.13M−$68.96M—
2022$0.00—−$77.04M−$73.32M—

Annual figures as reported, in the company's reporting currency. As of December 31, 2025.

Recent News

All 12 articles ↓

News provided by third-party sources. Not financial advice.

Analysis

Data-derived

Company Overview

The market values PMV Pharmaceuticals, Inc. (PMVP) at $102.70M. It is classified in the Biotechnology industry, within the Healthcare sector. The company reports 54 employees.

The 52-week range on file runs from $1.02 to $1.91. PMVP last closed at $1.36 on October 21, 2026. That is −$0.03 (−2.16%) against the previous close. The latest close sits 33.33% above that 52-week low.

Financial Health

The most recent full year on file, fiscal 2025, shows revenue of $0.00. The same year closed with a net loss of $77.74M. Trailing earnings per share are −1.42.

Across the 4 fiscal years on file, revenue moves from $0.00 in 2022 to $0.00 in 2025. Of those 4 years, 0 report positive net income.

Valuation Assessment

The record shows negative trailing earnings, so no price-to-earnings ratio is published.

Over the trailing twelve months the total return is −11.11%. Measured over 5 years, that is −43.28% a year compounded. Beta against the wider market is reported at 1.35. Annualized volatility over the trailing 6 years is 77.06%.

Growth & Income

No dividend is on file for PMVP.

So far in 2026 the total return is +8.80%. The strongest complete calendar year on file is 2025 at −17.22%; the weakest is 2023 at −64.37%. Of the 5 complete calendar years on file, 0 finished higher.

Peer Comparison

PMV Pharmaceuticals, Inc. (PMVP) operates in the Biotechnology industry. Here is how it compares to its closest peers by market capitalization:

Company Ticker Market Cap P/E Ratio
PMV Pharmaceuticals, Inc. PMVP $102.70M —
Vertex Pharmaceuticals Incorporated VRTX $132.95B 30.4
Moderna, Inc. MRNA $98.14B —
Regeneron Pharmaceuticals, Inc. REGN $82.95B 19.9

The Biotechnology industry average P/E ratio is 16.6x. PMV Pharmaceuticals, Inc. has no P/E ratio because it is not currently profitable.

Every figure above is read from this page's own data on each daily rebuild. Informational only, not financial advice. As of October 21, 2026.

Related Biotechnology Stocks

VRTX

Vertex Pharmaceuticals Incorporated

$132.95B

 MRNA

Moderna, Inc.

$98.14B

 REGN

Regeneron Pharmaceuticals, Inc.

$82.95B

 ARGX

argenx SE

$55.97B

 ONC

BeOne Medicines AG

$43.97B

 RVMD

Revolution Medicines, Inc.

$41.64B
View all Biotechnology stocks →

Popular Healthcare Stocks

LLY

Eli Lilly and Company

$1.13T

 JNJ

Johnson & Johnson

$621.22B

 ABBV

AbbVie Inc.

$503.27B

 UNH

UnitedHealth Group Incorporated

$374.30B

 MRK

Merck & Co., Inc.

$369.78B
View all Healthcare stocks →

About PMV Pharmaceuticals, Inc.

PMV Pharmaceuticals, Inc., a precision oncology company, engages in the discovery and development of small molecule therapies targeting p53 mutations and other p53-related cancers in the United States. It develops rezatapopt, a selective structural corrector of p53 Y220C mutations in Phase 2 clinical trials for tumor agnostic diseases. The company was formerly known as PJ Pharmaceuticals, Inc. and changed its name to PMV Pharmaceuticals, Inc. in July 2013. PMV Pharmaceuticals, Inc. was incorporated in 2013 and is headquartered in Princeton, New Jersey.

Visit website →